DEF: HealthEquity Reports Strong FY26 Growth, Proposes New Equity Plans

HealthEquity, Inc. announced robust financial and operational results for fiscal year 2026, including significant increases in revenue, net income, and HSA assets, alongside proposals for new employee equity incentive plans.

Summary

• Overall revenue reached $1.313 billion, marking a 9% increase from the fiscal year ended January 31, 2025.
• Net income surged by 123% to $215.2 million, compared to $96.7 million in the prior fiscal year.
• Net income per diluted share increased by 126% to $2.46, up from $1.09 in the previous fiscal year.
• Adjusted EBITDA grew by 20% to $566.0 million.
• Health Savings Accounts (HSAs) totaled 10.6 million, a 7% increase, with 1,040,000 new HSAs from sales.
• Total Accounts, including HSAs and complementary consumer-directed benefits (CDBs), reached 17.8 million, a 4% increase.
• HSA Assets grew by 14% to $36.5 billion as of January 31, 2026.
• The company repurchased 3.3 million shares of its common stock for $301.7 million.
• HSA cash repricing risk was further reduced with a cumulative $2.35 billion 5-year Treasury bond hedge at 3.92%.
• The board of directors proposes the election of ten directors, ratification of PricewaterhouseCoopers LLP as independent auditor, an advisory vote on executive compensation, and approval of the 2026 Employee Stock Purchase Plan and the Amended and Restated 2024 Equity Incentive Plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive filing, highlighting strong financial and operational growth, effective risk management, and a commitment to robust corporate governance and employee incentives.

Positives

• Overall revenue increased by 9% to $1.313 billion.
• Net income increased by 123% to $215.2 million.
• Net income per diluted share increased by 126% to $2.46.
• Adjusted EBITDA increased by 20% to $566.0 million.
• Health Savings Accounts (HSAs) grew by 7% to 10.6 million.
• Total Accounts, including HSAs and complementary CDBs, increased by 4% to 17.8 million.
• HSA Assets increased by 14% to $36.5 billion.
• The company repurchased 3.3 million shares of common stock for $301.7 million, demonstrating capital return to shareholders.
• Successfully reduced HSA cash repricing risk with a $2.35 billion 5-year Treasury bond hedge at 3.92%.

Negatives

• New HSA sales of 1,040,000 were below the target level of 1,170,000 for the Fiscal 2026 Executive Bonus Plan.

Risks

• General strategic, financial, cyber, business and operational, legal and compliance, and reputational risks.
• Cybersecurity threats, data security systems, fraud programs, and potential breach incidents.
• Compliance with applicable information security and data protection laws and industry standards.
• Risks associated with artificial intelligence (AI) initiatives and AI threats.
• Capacity, performance, and reliability of technology platforms.
• Risk of excessive or inappropriate risk-taking encouraged by compensation policies and practices.
• Corporate social responsibility matters, including environmental, social, and governance sustainability matters.
• Potential for related person transactions to create conflicts of interest.
• Violations of the Insider Trading Policy.
• Tax consequences related to executive compensation, including Sections 162(m), 280G, 4999, and 409A of the Code.
• Accounting considerations for stock-based compensation under FASB ASC Topic 718.

Future Outlook

The company's future outlook includes continued focus on its core financial and business objectives, with the Fiscal 2027 Executive Bonus Plan targeting revenue and Adjusted EBITDA, and incorporating strategic growth modifiers for marketplace and investment revenue and net new HSAs. The proposed Amended and Restated 2024 Equity Incentive Plan aims to secure and retain highly qualified individuals to help meet future goals, ensuring competitiveness in the industry.

Management Comments

• Our executive compensation program is guided by our overarching philosophy of only paying for demonstrable performance.
• We believe that our executive compensation program is reasonable, competitive, and appropriately balances the goals of attracting, motivating, rewarding, and retaining our executive officers.
• We emphasize performance-based compensation that appropriately rewards our executive officers for delivering financial, operational, and strategic results that meet or exceed pre-established goals.

Industry Context

StockSavvy.ai notes that HealthEquity's strong growth in HSAs and assets, coupled with robust financial performance, positions it favorably within the consumer-directed healthcare benefits sector. The strategic hedging of HSA cash repricing risk demonstrates proactive financial management, a key differentiator in a volatile interest rate environment. The focus on technology and AI oversight through a dedicated committee reflects broader industry trends towards digital transformation and managing associated cyber risks.

Comparison to Industry Standards

• HealthEquity's 9% revenue growth and 123% net income increase for FY26 are strong indicators, potentially outperforming some peers in the financial services and healthcare technology sectors.
• The 20% Adjusted EBITDA growth suggests efficient operations compared to industry averages.
• The $2.35 billion 5-year Treasury bond hedge at 3.92% for HSA cash repricing risk is a specific financial instrument demonstrating sophisticated risk management, comparable to practices seen in larger financial institutions or specialized asset management firms.
• The updated compensation peer group for FY27, including companies like BILL Holdings, Affirm Holdings, SoFi Technologies, Hims & Hers Health, Manhattan Associates, Jack Henry & Associates, Waystar Holding Corp., and Doximity, Inc., suggests a strategic shift towards benchmarking against higher-growth, more digitally-focused financial and healthcare technology companies, indicating an ambition to compete for top talent in these dynamic segments.

Management Changes

Corporate Governance

Related Party Transactions

• The Company has an Employer Services Agreement with The Vanguard Group, Inc. (a beneficial owner of >5% until Jan 12, 2026), through which the Company provides HSAs to Vanguard employees. The Company received $381,439 during FY26.
• The Company has a Client Referral and SSO Agreement with The Vanguard Group, Inc., through which Vanguard may refer clients for HSAs. The Company paid Vanguard $782,125 during FY26.
• The Company has a Master Services Agreement with BlackRock, Inc. (a beneficial owner of >5%), through which the Company provides consumer-directed benefits to BlackRock employees. BlackRock paid the Company $297,367 during FY26, and the Company expects to receive over $120,000 in FY27.
• The Company has an agreement with Sanford Health (where director William Gassen is President and CEO) to provide consumer-directed benefits to Sanford employees. The Company received $123,923 during FY26 and expects to receive over $120,000 in FY27.
• The Company has entered into indemnification agreements with its directors and certain executive officers.

Stakeholder Impact

• Shareholders: Expected to benefit from strong financial performance, share repurchases, and executive compensation aligned with performance. Potential dilution from new equity plans is managed by governance features.
• Employees: Will benefit from the proposed 2026 Employee Stock Purchase Plan and the Amended and Restated 2024 Equity Incentive Plan, offering opportunities for stock ownership and long-term incentives, enhancing retention and motivation.
• Customers: Continued growth in HSAs and total accounts suggests ongoing and expanding service offerings in consumer-directed healthcare benefits.
• Management: Incentivized by performance-based compensation and long-term equity awards, aligning their efforts with the company's strategic and financial objectives.
• Creditors: Strong financial health and risk management practices, including hedging, contribute to the company's stability and ability to meet obligations.

Next Steps

• Stockholders will vote on the election of ten directors at the Annual Meeting on June 25, 2026.
• Stockholders will vote on the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending January 31, 2027.
• Stockholders will cast a non-binding, advisory vote on the fiscal 2026 compensation paid to named executive officers.
• Stockholders will vote on the approval of the HealthEquity, Inc. 2026 Employee Stock Purchase Plan.
• Stockholders will vote on the approval of the Amended and Restated HealthEquity, Inc. 2024 Equity Incentive Plan.
• The board of directors will continue its ongoing refreshment process, including refreshing committee leadership and membership.
• The compensation committee will conduct annual reviews of the executive compensation program and the compensation peer group.
• The board of directors will conduct an annual review of committee charters and key governance policies.
• The company expects to engage with its stockholders on a regular basis.
• The initial offering period for the 2026 Employee Stock Purchase Plan is expected to commence in September 2026.
• Subsequent offering periods for the 2026 Employee Stock Purchase Plan are expected to occur every six months on April 1 and October 1.
• The next required advisory vote on the frequency of future say-on-pay votes will occur at the 2029 annual meeting of stockholders.
• Stockholder recommendations for director candidates for the 2027 annual meeting must be submitted no earlier than February 25, 2027, and no later than March 27, 2027.
• Stockholder proposals for inclusion in the 2027 annual meeting proxy materials (Rule 14a-8) must be received by February 25, 2027.

Key Dates

Recommendation

The company demonstrates exceptional financial performance with significant growth in revenue, net income, and Adjusted EBITDA, alongside robust expansion in HSA and total accounts. Strategic share repurchases and proactive risk management, such as the Treasury bond hedge, indicate sound capital allocation and financial stewardship. The proposed equity plans and compensation structure further align management and employee interests with long-term shareholder value creation. While new HSA sales were slightly below target, the overall picture is one of strong execution and positive momentum in a growing market, making it an attractive investment.

Keywords

HealthEquity, HSA, Health Savings Accounts, Consumer-Directed Benefits, Financial Services, Healthcare Technology, Proxy Statement, Executive Compensation, Corporate Governance, Equity Incentive Plan, Employee Stock Purchase Plan, Adjusted EBITDA, Revenue Growth, Net Income, Share Repurchase, Risk Management, Cybersecurity